Thursday, July 28, 2011 12:37:59 PM
I can't send private messages w/o a premium membership.
So... I feel the price has been discounted due to this:
The company said that it expects to report net revenue of approximately $12.0 million, up 104% y/y but short of analyst estimates of over $14 million. Approximately $2 million of orders received in the second quarter were unable to be shipped by June 30, primarily due to the timing of a significant change order placed by Henry Schein and the resulting last minute delays of critical components. Biolase originally planned its second quarter production and organized its supply chain accordingly, anticipating that it would continue to produce iLase systems in order to fulfill the final $3 million of the $9 million of purchase orders from Schein with the iLase system. This prepaid purchase order gives Schein certain rights and priority of delivery. Some critical components have long lead times and require orders to be placed months in advance. Schein informed the company that it was changing its order from iLase systems to a combination of the Waterlase iPlus and, to a lesser extent, the ezlase, on April 28, well after the start of the second quarter.
I know BioLases products are best in class and they are being awarded multiple patents into expanding treatment fields:
http://www.marketwatch.com/story/biolase-issued-new-patents-that-strengthen-its-expansion-into-the-treatment-of-eye-conditions-including-presbyopia-2011-07-14?reflink=MW_news_stmp
They are opening offices in India & China
They just announced: BIOLASE Reports First Orders for the BIOLASE DaVinci ImagingTM Systems for Delivery in Q-3
http://pr-usa.net/index.php?option=com_content&task=view&id=833087&Itemid=30
All of this (plus plenty of other things I didn't have time to list) points towards a promising future for BioLase.
I am just glad I got the chance to rebuy at this level.
Recent BIOL News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2024 08:05:08 PM
- Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities • Edgar (US Regulatory) • 09/06/2024 11:39:45 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:30:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:05:53 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM